AXON - Axovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.82
-0.08 (-2.76%)
At close: 4:00PM EDT

2.74 -0.08 (-2.84%)
Pre-Market: 8:00AM EDT

Stock chart is not supported by your current browser
Previous Close2.90
Open2.92
Bid2.76 x 2200
Ask2.84 x 1300
Day's Range2.80 - 3.00
52 Week Range1.02 - 27.98
Volume2,442,292
Avg. Volume5,351,935
Market Cap344.249M
Beta-0.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire3 days ago

    Axovant to Present at First Annual Roivant Pipeline Day

    Axovant Sciences (AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET. A live webcast will be available in the Investors section of Axovant's website at www.axovant.com. Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.

  • ACCESSWIRE13 days ago

    Wired News – Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinson’s Treatment

    LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Axovant Sciences Ltd (NASDAQ: AXON) ("Axovant"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXON as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has signed an exclusive worldwide licensing deal with Oxford BioMedica to develop and commercialize OXB-102 (now AXO-Lenti-PD), a gene therapy developed by Oxford BioMedica for Parkinson's disease utilizing the LentiVector® platform. Active-Investors.com is currently working on the research report for ProQR Therapeutics N.V. (NASDAQ: PRQR), which also belongs to the Healthcare sector as the Company Axovant Sciences.

  • ACCESSWIRE14 days ago

    Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Axovant Sciences was one of the biggest gainers in the stock market on Wednesday after announcing that it has licensed an investigational gene therapy for Parkinson's Disease from Oxford BioMedica. Shares of Heat Biologics also climbed a lot higher despite any news. The company's CEO was said to present at the 2018 BIO International Convention on Wednesday.

  • ACCESSWIRE14 days ago

    57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS

    Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Growing their sales consistently, and partnered with high-profile public clients, ORGS could be significantly undervalued with continued executiona and expansion. NEW YORK, NY / ACCESSWIRE / June 7, 2018 / The curative potential of gene and cell therapies has kept these new pharmaceutical products front and center for healthcare investors for the last 3 years.

  • GlobeNewswire15 days ago

    Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition

    Axovant Sciences (AXON) today announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from Oxford BioMedica. AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain.

  • ACCESSWIRE17 days ago

    Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).

  • GlobeNewswire21 days ago

    Axovant to Present at Two Upcoming Investor Conferences

    BASEL, Switzerland, May 31, 2018-- Axovant Sciences today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference ...

  • ACCESSWIRE22 days ago

    Today’s Research Reports on Stocks to Watch: Axovant Sciences and Johnson & Johnson

    NEW YORK, NY / ACCESSWIRE / May 30, 2018 / Biotech company Axovant shares saw a breakout in Tuesday trading after the company announced a new add to its executive team. Shares of Johnson & Johnson were slightly in the red after it was revealed that a jury was hung in South Carolina over whether the company's baby powder caused a woman cancer. The company also said it would be participating in the Goldman Sachs 39th Annual Global Healthcare Conference next month.

  • GlobeNewswire23 days ago

    Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion

    Axovant Sciences (AXON) today announced that Gavin Corcoran, MB BCh, FACP, will join the Company as Executive Vice President of Research & Development, and Michael Hayden, MB ChB, PhD, FRSC, has been appointed as a senior scientific advisor to the company and Chairman of Axovant’s newly established Scientific Advisory Board. “I am pleased to welcome Gavin and Michael to the Axovant team,” said Pavan Cheruvu, MD, Chief Executive Officer of Axovant.

  • Business Wire4 months ago

    AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors

    Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd. investors concerning the Company and its officers’ possible violations of federal securities laws.

  • ACCESSWIRE9 months ago

    Today's Research Reports on Stocks to Watch: Axovant and Moleculin

    NEW YORK, NY / ACCESSWIRE / September 27, 2017 / Shares of Axovant were clobbered yesterday after the company released an update on its late-stage Alzheimer’s trial that revealed the trial did not meet ...

  • PR Newswire9 months ago

    Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease

    BASEL, Switzerland, Sept. 26, 2017 /PRNewswire/ -- Axovant Sciences (AXON) today announced that the Phase 3 MINDSET clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease (AD) who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition or in measures of activities of daily living as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), respectively, compared to patients treated with placebo.

  • PR Newswire9 months ago

    Axovant to Present at Two Upcoming Investor Conferences

    BASEL, Switzerland , Sept. 6, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced upcoming presentations by David Hung , M.D., chief executive officer of Axovant, on September 6, 2017 at ...

  • ACCESSWIRE10 months ago

    Featured Company News - AVEO Pharma's FOTIVDA(R) Licensed in EU for the Treatment of Advanced Renal Cell Carcinoma

    Research Desk Line-up: Axovant Sciences Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • PR Newswire10 months ago

    Axovant to Move Stock Exchange Listing to Nasdaq

    BASEL, Switzerland, Aug. 21, 2017 /PRNewswire/ -- Axovant Sciences (AXON) today announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market. "Nasdaq is a great fit for Axovant as it is home for leading biotechnology companies and we are honored to now be among them," said David Hung, M.D., chief executive officer of Axovant.

  • PR Newswire10 months ago

    Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates

    BASEL, Switzerland , Aug. 7, 2017 /PRNewswire/ -- Axovant Sciences (NYSE:  AXON ) today announced financial results for the three months ended June 30, 2017 as well as general business updates. Key Highlights ...

  • PR Newswire11 months ago

    Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman

    BASEL, Switzerland, July 10, 2017 /PRNewswire/ -- Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapies in medical dermatology, today announced the appointment of Dr. Jacqualyn "Jackie" Fouse as Executive Chairman. "I am honored to lead Dermavant and look forward to building the world's leading innovative medical dermatology company," said Dr. Fouse.

  • PR Newswire11 months ago

    Axovant to Present Key Intepirdine and Nelotanserin Data at Alzheimer's Association International Conference

    BASEL, Switzerland , July 10, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced a number of upcoming presentations relating to its intepirdine and nelotanserin programs at the 2017 Alzheimer's ...

  • Accesswirelast year

    Earnings Review and Free Research Report: Axovant Sciences Reported Lower than Expected Earnings

    LONDON, UK / ACCESSWIRE / June 29, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Axovant Sciences Ltd (NYSE: AXON ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=AXON ...